CRSP vs EDIT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRSP Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin, Momentum & Technical while EDIT counters with relative strength in Options & Structure. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus EDIT at N/M Forward P/E and -167.0% operating margin (+37.4% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRSP Revenue | EDIT Revenue | CRSP Op. Margin | EDIT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $30M | -5087.8% | -356.1% | EDIT |
| FY2019 | $290M | $20M | 16.1% | -686.4% | CRSP |
| FY2020 | $0M | $90M | -49295.5% | -148.6% | EDIT |
| FY2021 | $910M | $30M | 40.8% | -756.1% | CRSP |
| FY2022 | $0M | $20M | -56190.4% | -1146.3% | EDIT |
| FY2023 | $370M | $80M | -60.0% | -216.6% | CRSP |
| FY2024 | $40M | $30M | -1250.4% | -777.2% | EDIT |
| FY2025 | $0M | $40M | -18933.6% | -394.9% | EDIT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRSP | EDIT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.1B | $336.5M | Larger Scale | CRSP |
| Trailing P/E Ratio Valuation | 23.4x | N/M | Lower Multiple | CRSP |
| Forward P/E Ratio Valuation | 23.4x | N/M | Lower Multiple | CRSP |
| Revenue Growth (YoY) Growth | +1325.1% | +37.4% | Higher Growth | CRSP |
| Operating Margin (TTM) Profitability | -2058.6% | -167.0% | Higher Margin | EDIT |
| Net Profit Margin Profitability | 0.0% | -144.9% | Higher Margin | CRSP |
| Return on Equity (ROE) Capital Efficiency | -25.6% | -147.4% | Higher ROE | CRSP |
| 52-Week Range Position Momentum | 1% ($40โ$63) | 11% ($2โ$4) | Stronger Trend | EDIT |
| Beta / 30D Volatility Risk Regime | 1.85ฮฒ ยท 60% Vol | 2.32ฮฒ ยท 102% Vol | Lower Realized Risk | CRSP |
| Unified Institutional Score Composite Signal | 48.6 / 100 (HOLD) | 51.6 / 100 (HOLD) | Higher Composite | EDIT |